A Multicentre, Open-label, Extension Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Oxcarbazepine (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Apr 2017 Planned End Date changed from 1 Feb 2017 to 20 Dec 2017.
- 20 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 20 Dec 2017.
- 20 Jul 2016 Planned End Date changed from 1 May 2016 to 1 Feb 2017.